2.42

7.08% 0.16

After Hours: 2.45 0.03 +1.24%

Adc Therapeutics Sa (ADCT)

Overview News Price History Option Chain Discussions Forecast

Adc Therapeutics Sa stock is traded at $2.42, with a volume of 240.89K. It is up +7.08% in the last 24 hours and down -19.60% over the past month. ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Previous Close:

$2.26

Open:

$2.28

24h Volume:

240.89K

Relative Volume:

0.64

Market Cap:

$233.99M

Revenue:

$69.56M

Net Income/Loss:

$-240.05M

P/E Ratio:

-1.0661

EPS:

-2.27

Net Cash Flow:

$-121.90M

1W Performance:

+21.61%

1M Performance:

-19.60%

6M Performance:

-27.33%

1Y Performance:

+214.29%

1-Day Range:

$2.26

$2.46

1-Week Range:

$1.91

$2.46

52-Week Range:

$0.8094

$6.04

Adc Therapeutics Sa Stock (ADCT) Company Profile

Name

Adc Therapeutics Sa

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

41 21 653 02 00

Address

BIOPOLE, EPALINGES

Employee

274

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ADCT's Discussions on Twitter

Compare ADCT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADCT Adc Therapeutics Sa	2.42	233.99M	69.56M	-240.05M	-121.90M	-2.95
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Initiated	Stephens	Overweight
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-06-22	Initiated	CapitalOne	Overweight
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-21	Initiated	Wolfe Research	Outperform
Aug-17-21	Resumed	Jefferies	Buy
Aug-09-21	Initiated	RBC Capital Mkts	Outperform
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight
Dec-03-20	Initiated	Stifel	Hold
Oct-29-20	Initiated	H.C. Wainwright	Buy
Jun-09-20	Initiated	BofA/Merrill	Buy
Jun-09-20	Initiated	Cowen	Outperform

View All

Adc Therapeutics Sa Stock (ADCT) Latest News

Nov 29, 2024

ADC Therapeutics to Host Third Quarter 2024 Financial Results Co - GuruFocus.com

Nov 29, 2024

Nov 28, 2024

ADC Therapeutics to Present at November Investor Conferences - GuruFocus.com

Nov 28, 2024

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - GuruFocus.com

Nov 28, 2024

Nov 26, 2024

Antibody Drug Conjugate Market Industry Trends and Forecasts to 2035, Featuring Profiles of Key Players ADC Therapeutics, Byondis, Daiichi Sankyo, Genentech, Gilead Sciences, ImmunoGen, RemeGen and More - Yahoo Finance

Nov 26, 2024

Nov 23, 2024

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Fin - GuruFocus.com

Nov 23, 2024

ADC Therapeutics Announces Investigator-Initiated Study Abstract - GuruFocus.com

Nov 23, 2024

Nov 20, 2024